Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 85%
filed 2026-10-23
EX-99.1
This exhibit is a Phase 1 clinical trial presentation for IMA203CD8, Immatics' PRAME-directed TCR T-cell therapy, disclosing efficacy and safety results from a multicenter study (IMA203-101). The presentation reports a 51% objective response rate (ORR) across 90 evaluable patients with PRAME+ solid tumors, including gynecologic cancers, melanoma, and synovial sarcoma, with manageable tolerability and no dose-limiting maximum tolerated dose reached. This represents material clinical progress on a key pipeline asset that would affect investor assessment of the company's development trajectory and competitive position in cell therapy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 80%
filed 2026-10-23
EX-99.1
HudBay Minerals completed and disclosed a Definitive Feasibility Study (DFS) for the Copper World Project in Arizona, including updated mineral reserve and resource estimates, mine design, capital and operating cost projections, and economic analysis. The DFS represents a material operational milestone affecting investor assessment of the project's economics, timeline, capital requirements, and the company's development pipeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-23
Item 8.01
Cumberland announced top-line results from a Phase 2a clinical trial (ASSIST-SSc) for ifetroban in systemic sclerosis, demonstrating safety and tolerability. This is a material clinical milestone for a pharmaceutical company's drug development program, but does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant development in the company's pipeline—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-23
Item 8.01
MacroGenics disclosed positive interim Phase 1 clinical trial results for MGC026, a B7-H3-directed antibody-drug conjugate, showing a 27% response rate in heavily pretreated SCCHN patients with a manageable safety profile. The company announced plans to initiate a front-line combination study with pembrolizumab in early 2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, exec changes, M&A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity, dilutive issuance, litigation, debt/dividend issuance, or workforce reduction. It is clearly operational/strategic in nature—a significant product development update—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-23
Item 8.01
Ionis disclosed positive Phase 3 clinical trial data for sefaxersen, a partnered investigational drug licensed to Roche, showing a statistically significant 43.1% reduction in proteinuria in IgA nephropathy patients with a consistent safety profile. This material clinical milestone affects investor assessment of the drug's commercial potential and Ionis' future royalty and milestone payments from the partnership.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-23
EX-99.1
This press release announces positive three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate, showing 89% vaccine target precision, sustained T-cell responses, and durable clinical responses in advanced melanoma patients. While the disclosure reports clinical trial results rather than financial results or a discrete corporate event, it represents a material operational milestone for a clinical-stage biotech company—the data supports advancement of the company's lead asset and validates its AI-Immunology platform technology. This is neither a periodic financial report nor a traditional earnings release, but rather a material clinical/operational development that would affect investor assessment of the company's pipeline and technology platform.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-23
Item 7.01
Wynn Resorts' indirect subsidiary Wynn Macau (Macau) S.A. entered into a subscription agreement to commit capital investment of up to MOP 1,365,030,000 to a Macau government-sponsored limited partnership fund. The investment constitutes non-gaming capital commitment under the company's gaming concession contract with the Macau government dated December 16, 2022. This is a material operational and strategic commitment to fulfill regulatory obligations in a key jurisdiction, but does not fit the specific categories of M&A activity, debt issuance, or other defined event types—it is a material capital commitment and regulatory compliance matter best classified as operational_other.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-23
EX-99
This press release announces preclinical data presented at ESMO 2026 demonstrating synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, with plans to add an ovarian cancer arm to the ongoing Phase 1/2a clinical trial. The disclosure is a material operational/strategic milestone—positive preclinical results supporting expansion of a lead program into a new indication—but does not fit the discrete event categories (no M&A, no exec change, no financial obligation, no litigation). The data presentation and planned trial expansion represent a significant development in the company's therapeutic pipeline and clinical strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-23
EX-99.1
Melco Macau, an indirect subsidiary of Melco International Development Limited, entered into a limited partnership agreement on 23 October 2026 to subscribe for interests in the Macao SAR Government Guidance Fund No. 2 with a capital commitment of MOP828.0 million (approximately HK$803.2 million), representing 9.2% of aggregate commitments. The announcement explicitly states this constitutes a "discloseable transaction" under Hong Kong Listing Rules Chapter 14 (highest applicable percentage ratio is 5% or more but less than 25%). While the investment is made to fulfill non-gaming investment obligations under the Concession Contract and is not expected to materially affect the Company's financial position, the transaction involves a material capital commitment to a government-sponsored fund and represents a strategic operational/investment decision by the Company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-23
Item 8.01
Tango announced updated Phase 1/2 clinical trial results for vopimetostat in combination with RAS(ON) inhibitors, demonstrating an 82% objective response rate and 88% 9-month progression-free survival in pancreatic cancer patients, with plans to initiate a Phase 3 registrational trial in the first half of 2027. The company also disclosed a strategic reprioritization approved by the Board to focus on PRMT5-targeted therapies and deprioritize novel target discovery, accompanied by a planned approximately 14% workforce reduction.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-23
Item 8.01
ORIC Pharmaceuticals disclosed positive Phase 1b clinical trial data for enozertinib (ORIC-114) in EGFR atypical NSCLC patients, showing 84% systemic ORR and 70% CNS ORR with favorable safety profile, and announced plans to initiate a global Phase 3 registrational trial (Redwood-1) in the first half of 2027.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-23
Item 8.01
Aardvark disclosed exploratory efficacy and safety data from its terminated Phase 3 HERO trial and open-label extension trial for ARD-101, along with the FDA's lifting of the clinical hold and plans to resume clinical activities in 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company—the data disclosure, regulatory clearance, and path-forward announcement would affect a reasonable investor's assessment of the drug development program's viability. While the data are explicitly labeled "exploratory" due to early termination, the convergence of efficacy signals, safety profile, and regulatory progress constitute a significant operational development that does not fit neatly into the specific financial, governance, or legal categories.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-23
Item 8.01
Tempus announced a series of material commercial agreements with Bristol-Myers Squibb and Pathos AI totaling $192.5 million in aggregate cash payments over five years. The disclosure covers licensing of de-identified oncology and neurology data, software tools, and related services—a significant strategic partnership and revenue-generating arrangement. While this is a material operational and commercial event, it does not fit the specific categories of M&A activity, debt issuance, or other named financial events; it is best classified as a material operational/strategic business arrangement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-23
NovaBridge reports presentation of clinical trial data for ragistomig (ABL503/TJ-L14B), a bispecific antibody in Phase 1 development, at the ESMO Congress 2026. This is a material operational milestone for a bioscience company — clinical trial progress and data presentation at major medical conferences are significant events affecting investor assessment of pipeline advancement and competitive positioning. The disclosure does not fit a more specific category (not earnings, M&A, litigation, or governance), making operational_other appropriate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-23
Item 8.01
Eikon disclosed clinical trial data for three drug candidates (EIK1003, EIK1004, EIK1005) presented at the 2026 ESMO Congress, including Phase 1/2 safety and efficacy results, objective response rates, adverse event profiles, and dose-escalation findings across multiple cohorts and combination strategies.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-23
Item 8.01
Bolt disclosed Phase 1 clinical trial results for BDC-4182, a claudin 18.2-targeting antibody in gastric cancer, showing tolerability with mostly Grade 1/2 adverse events, no dose-limiting toxicities, and a 53% disease control rate in the every-2-weeks cohort.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-23
Item 8.01
Perspective Therapeutics announced updated interim Phase 1/2a clinical trial results for [212Pb]VMT-α-NET presented at ESMO Congress 2026, showing encouraging efficacy (33–50% ORR across cohorts), durable disease control (72% PFS at 18 months), and favorable safety profile (no dose-limiting toxicities, no treatment discontinuations). The company is advancing toward Phase 3 site preparation with expected initiation in 2027. This is a material clinical development milestone for a radiopharmaceutical company with a single lead program, affecting investor assessment of pipeline progress and regulatory pathway viability.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-23
EX-99.2
Black Mammoth Metals' common shares commenced trading on Nasdaq Capital Market under ticker 'BMMX' on October 15, 2026, following SEC approval of a Form 40-F registration statement, with simultaneous delisting from the OTC Pink Limited Market. This listing transfer represents a material strategic milestone enhancing the registrant's market access and visibility.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-23
Item 8.01
Climb Bio announced positive Phase 1 clinical trial data for CLYM116/MIL116 presented at ASN Kidney Week 2026, demonstrating favorable pharmacokinetic and pharmacodynamic results including ~70% Gd-IgA1 reduction, >90% APRIL suppression, and a ~33-day half-life supporting Q12W dosing. The data support advancement to Phase 2 (NAVIGATE-2, currently enrolling) and planned Phase 3 initiation in 2027, representing a material clinical development milestone for the company's lead program in IgA nephropathy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-23
EX-99.1
This press release announces a significant operational and clinical milestone for SciSparc's subsidiary NeuroThera: successful completion of manufacturing and European QP batch release certification for SCI-110, completion of site initiation activities across three clinical centers, and advancement toward patient enrollment in an FDA-approved Phase IIb clinical trial for Tourette Syndrome. While this is a positive development in an ongoing drug development program rather than a discrete financial event, M&A activity, or executive change, it represents material progress in a key clinical program that would affect a reasonable investor's assessment of the company's pipeline advancement and near-term operational trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-23
Item 1.01
Treasure Global's subsidiary Tadaa entered into a material software development agreement with Techcom Vintage to build a Government Smart Fertilizer Traceability & AI Agriculture Intelligence Platform for RM8,000,000. This is a significant operational and strategic contract involving multi-phase development, government subsidy program support, and substantial fixed fees, but it does not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor does it fit other specific event categories. The agreement is material to investors as it represents a major business initiative and capital commitment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-23
EX-99.1
This announcement discloses positive Phase 3 clinical trial results for rinatabart sesutecan (Rina-S®) in platinum-resistant ovarian cancer, meeting primary and key secondary endpoints (PFS and OS with statistically significant improvements). While this is a material clinical milestone for a biotech company's pipeline advancement and regulatory pathway, it does not fit the discrete event categories (not an earnings release, M&A, executive change, or financial obligation). The disclosure is clearly operational/strategic—a major product development milestone—making `operational_other` the most appropriate classification for a material clinical trial success that will inform regulatory discussions and future commercialization strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-23
EX-99.1
The exhibit announces a strategic business restructuring: the Board-approved wind-down and dissolution of mF International's legacy financial trading solutions business (m-Finance Limited and two subsidiaries) with a complete pivot to digital asset operations (Bitcoin Cash treasury, self-mining, and insurance initiatives). This is a material operational and strategic shift that would affect a reasonable investor's assessment of the company's business model and future direction, though it does not fit the specific categories of M&A activity, workforce reduction, or material impairment—it is a deliberate strategic repositioning disclosed as a press release.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-23
EX-99.2
HomesToLife announced receipt of a conditional eligibility-to-list letter from Singapore Exchange and issuance of an Introductory Document for a proposed secondary listing on SGX-ST Mainboard. This is a material capital markets milestone reflecting the company's strategic expansion into Asia-Pacific and broadening of its investor base, though completion remains subject to satisfaction of conditions and is not assured. The event is operational/strategic rather than a discrete financial transaction (like debt issuance or M&A), making operational_other the best fit.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-23
Item 7.01
Zai Lab published an updated corporate presentation on October 23, 2026, disclosing clinical trial data and development updates for its lead oncology program (Zoci/zocilurtatug pelitecan), including ESMO 2026 data showing an 81.8% ORR with the doublet regimen in first-line SCLC and a favorable tolerability profile. This material clinical milestone disclosure affects investor assessment of the company's drug development trajectory and commercial prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-23
Item 7.01
This is a shareholder letter disclosing a strategic reset and operational restructuring. The company announces a shift to a focused payments infrastructure strategy, consolidation onto a single platform (launching before year-end), leadership changes (new Interim CTO and compliance hires), and four new growth initiatives (credit card issuance, digital asset conversions, bank yield program, compliance-as-a-service). The letter explicitly states "we expect growth to slow or decrease during the second half of the year" due to winding down legacy platforms and addressing operational challenges. While this is clearly material to investors (affecting strategic direction and near-term financial outlook), it does not fit neatly into specific categories like ma_activity, workforce_reduction, or exec_appointment—it is a comprehensive operational and strategic repositioning disclosed via Regulation FD.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-23
Item 8.01
High Roller Technologies announced the commercial launch of ROLR™, its real-money prediction markets platform, on October 21, 2026, marking entry into a new business line with expected revenue contribution beginning in Q4 2026. This is a material operational and strategic milestone—a significant product launch backed by established marketing partnerships and technology infrastructure—but does not fit the specific categories of earnings release, M&A activity, or other named event types. The disclosure centers on a major business expansion and operational milestone rather than financial results, executive changes, or capital transactions.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-22
Item 1.01
Lee Enterprises entered into Master Service Agreements with Quintype Solutions LLC for software development services on October 16, 2026. While the filing is disclosed under Item 1.01 (Entry into a Material Definitive Agreement), the substance is a multi-year operational services contract with a related party (Quint Digital holds 14.38% of LEE's stock and over 10% of Quintype), expected to generate over $1 million in annual net savings and strengthen AI capabilities. This is a material operational/strategic partnership rather than an M&A transaction, making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-22
EX-99.1
This news release discloses assay results from a completed 14-hole drilling program at Canagold's New Polaris Gold Project, reporting high-grade gold and antimony intercepts (e.g., 69.8 g/t Au over 2.64m, 52.8 g/t Au and 0.83% Sb over 4.64m). The CEO emphasizes that "most of these high-grade intervals are not included in the current mineral resource model" and that results "suggest that the scale and extent of the high-grade gold and antimony mineralization may be substantially greater than previously understood," indicating material expansion potential for the resource. This is an operational/exploration milestone that would affect a reasonable investor's assessment of the project's economic viability and resource base.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-22
EX-99.1
This exhibit discloses a revised Preliminary Economic Assessment (PEA) and updated Mineral Resource Estimate (MRE) for New Found Gold's flagship Queensway Gold Project. The revised PEA shows significantly improved project economics (NPV5% of $1.7B, 126% IRR) and a 38% increase in Measured and Indicated Mineral Resources. While the document contains financial projections and technical details about the mining operation, it is fundamentally an operational/strategic disclosure about the development and expansion of the company's core asset and production timeline, rather than a discrete financial event (earnings release, debt issuance, etc.) or governance matter. The material nature is clear given the substantial improvement in project economics and resource base that would affect investor assessment of the company's path to production.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-22
Item 8.01
The disclosure announces FDA alignment on key design elements (patient selection, dose, duration, endpoints) for a Phase 3 pivotal trial of zervimesine in dementia with Lewy bodies. This is a material regulatory and clinical milestone for a clinical-stage biopharmaceutical company, representing progress toward a registrational study in an indication with no approved treatments. While not a specific named event type, this is clearly an operational/strategic advancement in the company's clinical development program that would affect a reasonable investor's assessment of the registrant's prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-22
Item 8.01
AmeriServ Bank has transitioned its investment services program to Ameriprise Financial Institution Group, a strategic partnership affecting the bank's wealth management operations and revenue model. The press release emphasizes this as part of a broader strategic plan to "grow the AmeriServ Wealth Management complex" and increase shareholder value, involving approximately $525 million in client assets under management. This is a material operational and strategic business event—a significant partnership or service transition—that does not fit the specific categories of M&A activity, debt issuance, or other named financial events, making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-22
EX-99.1
This exhibit is a press release announcing presentation of pre-clinical data on izicopan at Kidney Week 2026, demonstrating the drug's therapeutic potential in renal disease models. The disclosure highlights new structural modeling insights and positive efficacy signals in two kidney injury models (IRI and UUO), supporting advancement toward clinical development in ANCA-associated vasculitis and additional renal indications. While this is a research milestone rather than a discrete corporate event (M&A, executive change, financial obligation), it represents material operational progress on the company's lead program that would affect a reasonable investor's assessment of development trajectory and competitive positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-22
Item 8.01
The FDA's lifting of the clinical hold on AB-101's IND application is a material regulatory milestone that removes a significant development barrier for Arbutus' lead oral PD-L1 inhibitor program. This is a positive operational/regulatory event that enables continued clinical development, but does not fit the specific categories of earnings release, executive changes, M&A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. It is clearly operational in nature and material to investors assessing the company's pipeline progress.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-22
Item 8.01
Korro Bio disclosed preclinical results for KRRO-111, its development candidate for Alpha-1 Antitrypsin Deficiency, demonstrating >95% SERPINA1 mRNA editing and sustained restoration of functional M-AAT in repeat-dose studies. The company announced a regulatory submission expected in the first half of 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company advancing a pipeline program, but does not fit the specific categories of earnings release, M&A activity, or other named event types. The disclosure would affect a reasonable investor's assessment of the company's pipeline progress and near-term regulatory pathway.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-22
Item 8.01
The FDA's lifting of the clinical hold on ARD-101 is a material regulatory milestone that permits resumption of clinical development for Aardvark's lead program in Prader-Willi Syndrome. This is a significant operational and regulatory event—not a specific named type like earnings, M&A, or litigation—that directly affects the company's ability to advance its pipeline and would materially impact investor assessment of the registrant's prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-22
EX-99.1
This news release announces exploration progress at the Mustang Gold and Silver Property, including extension of the target zone, completion of an IP survey, acquisition of drill permits from the BLM, and confirmation of historic sampling results with new trench sampling (15 of 25 samples exceeding 0.100 g/t Au). The disclosure also reports staking of 54 new federal lode claims and grant of incentive stock options to directors and consultants. These are operational and strategic exploration milestones material to a mineral exploration company's advancement of its properties, though not a discrete M&A transaction, executive change, or financial event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-22
SK hynix clarifies that its subsidiary Solidigm has discontinued its review of pre-IPO capital raising and IPO plans after previously considering such financing measures. This is a material operational/strategic decision affecting the company's capital structure and subsidiary's growth trajectory, but does not fit a discrete event category (not a debt issuance, dilutive issuance, or M&A activity completed). The decision to abandon a significant financing initiative would affect investor assessment of the company's capital strategy and Solidigm's competitive positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-22
EX-99.1
Alpha Tau announced the signing of a Memorandum of Understanding (MOU) with Samsung Medical Center to explore a potential clinical trial of Alpha DaRT for pancreatic cancer patients in South Korea. This represents a material operational and strategic milestone—the company's first clinical trial in Korea and expansion of its pancreatic cancer program to a sixth country. While not a discrete M&A transaction, the MOU signals meaningful progress in the company's clinical development and geographic expansion strategy, which would affect a reasonable investor's assessment of the registrant's pipeline and market opportunities.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-22
EX-99.1
This press release announces a strategic collaboration agreement between Wearable Devices and Encord to combine neural-sensing wearable data with Physical AI data infrastructure. The agreement establishes a commercial framework for device sales and usage-based compensation, representing a material operational and commercial partnership that expands the company's addressable market into Physical AI and robotics applications. While not a discrete M&A transaction, the collaboration creates new revenue streams and strategic positioning that would affect a reasonable investor's assessment of the company's growth prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-22
Item 1.02
The filing discloses termination of a material marketing and sub-advisory services agreement between the Sponsor (21Shares US LLC) and ARK Investment Management LLC, effective December 22, 2026. This is a material operational event affecting the Trust's service provider relationships and brand identity, evidenced by the planned name change from "ARK 21Shares Bitcoin ETF" to "21Shares Bitcoin ETF" and ticker symbol change from ARKB to TBIT. While Item 1.02 typically covers M&A terminations, this disclosure centers on the termination of an ongoing service agreement rather than a material acquisition or disposition, making it an operational matter affecting the Trust's business continuity and marketing support.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-22
EX-99.1
Collective Mining disclosed an updated mineral resource estimate for the Apollo deposit at its Guayabales Project in Colombia, effective October 13, 2026, presenting detailed geological, exploration, and resource estimation data with tabulated mineral resources and recommendations for further work.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-22
EX-99.1
This news release announces Ballard's strategic business model expansion and financial targets disclosed at the Ballard Forum, including a shift to Energy-as-a-Service, 30% revenue CAGR targets, gross margin expansion to 20%+ by 2027 and 25%+ by 2028, and a path to adjusted EBITDA profitability by end of 2027. While the release contains forward-looking guidance rather than reported results, it discloses material strategic and operational initiatives (expanded business model, fleet expansion with $80–120M capex, and profitability targets) that would affect a reasonable investor's assessment of the company's direction and financial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-22
EX-99.1
This news release announces the filing of an independent NI 43-101 technical report supporting a maiden Mineral Resource estimate for the Apollo deposit at the Guayabales Project in Colombia. The disclosure details a significant exploration milestone—a 2.58 million ounce AuEq Indicated resource and 2.83 million ounce AuEq Inferred resource—which is material to investors' assessment of the company's asset base and development potential. While not a discrete operational event like a contract or partnership, this represents a material advancement of the company's flagship mineral property that would affect a reasonable investor's valuation of the exploration company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-22
Item 7.01
The disclosure announces a material operational milestone: completion of first product deliveries by affiliate SEA Craft to Illinois dispensaries following facility restart in June 2026, with initial 5,000 sq ft flowering canopy and planned expansion to 10,000 sq ft. This represents a significant market entry and operational achievement for the company's Illinois operations, but does not fit the specific categories of earnings release, M&A activity, or other named event types. The operational nature and materiality to investors assessing the company's growth trajectory and market expansion justify classification as operational_other.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-22
EX-99.1
This press release announces a positive interim milestone in Vicore's Phase 2b ASPIRE clinical trial: the independent Data Monitoring Committee recommended the trial continue without modification following a pre-planned futility analysis, with no safety concerns identified. The trial remains on track for mid-2027 topline results. This is a material operational/clinical development event for a clinical-stage biopharmaceutical company, as it demonstrates progress toward a key regulatory milestone and affects investor assessment of the company's lead program viability and cash runway. The disclosure does not fit discrete event categories like earnings_release, ma_activity, or exec changes, but represents a material clinical/operational milestone that would affect a reasonable investor's view of the company's prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-22
Item 1.01
Edible Garden AG entered into a Produce Supply Agreement with Caney Fork Farms, LLC on October 16, 2026, to purchase fresh produce for its core herb business with fixed pricing through January 31, 2027, and a committed volume schedule through October 15, 2028. This is a material operational contract governing a key input supply chain for the company's core business, but does not constitute a merger, acquisition, disposition, or other M&A activity. The agreement is material to investors as it secures supply continuity for the registrant's herb business operations.
View raw filing on EDGAR →
6-K
Operational Other
confidence 80%
filed 2026-10-22
EX-99.1
Gunnison Copper announced commencement of trading on NYSE American under ticker 'GUNN' effective October 26, 2026, via a Level II ADR program, representing a material strategic milestone that expands U.S. investor access and enhances the company's visibility in U.S. capital markets as an American copper producer.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-22
MIRA Pharmaceuticals disclosed positive preclinical study results for MIRA-55 in a chronic inflammatory pain model, demonstrating efficacy comparable to celecoxib without tolerance. The filing is disclosed under Item 7.01 (Regulation FD Disclosure) and represents a material operational/clinical development milestone supporting advancement toward an IND submission in Q1 2027. While not a traditional earnings release or financial event, the positive preclinical data is material to investors' assessment of the company's drug development pipeline and clinical prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-22
The filing discloses drill results from the 2026 reverse circulation program at the Lapon Canyon Gold Project, including significant gold intercepts (2.07 g/t Au over 47.3 metres). This is an operational/exploration milestone for a mining company with an earn-in agreement and royalty interest. While material to investors evaluating the company's project portfolio and exploration progress, it does not fit the specific event types (earnings release, M&A, impairment, etc.) and is best classified as an operational disclosure of exploration results under Item 7.01 Regulation FD Disclosure.
View raw filing on EDGAR →